Literature DB >> 25672347

Ventilator-associated pneumonia: epidemiology and prognostic indicators of 30-day mortality.

Juthamas Inchai1, Chaicharn Pothirat, Chalerm Liwsrisakun, Athavudh Deesomchok, Weerayut Kositsakulchai, Nipon Chalermpanchai.   

Abstract

We conducted a retrospective cohort study in the medical intensive care unit of Chaing Mai University Hospital to describe the epidemiology of ventilator-associated pneumonia (VAP) and identify prognostic indicators of 30-day VAP mortality. A total of 621 patients diagnosed with VAP between January 2005 and December 2011 were included. The overall 30-day mortality rate was 44.4%. The major causative pathogens were Acinetobacter baumannii (54.3%), Pseudomonas aeruginosa (35.2%), and methicillin-resistant Staphylococcus aureus (15.1%). Most A. baumannii (90.2%) comprised drug-resistant strains. Identified prognostic indicators were co-morbid malignancy (hazard ratio [HR] = 1.60; 95% confidence interval [CI] 1.02-2.42; P = 0.040), septic shock (HR = 2.51; 95% CI, 1.60-4.00; P < 0.001), Simplified Acute Physiology Score II >45 (HR = 1.62; 95% CI, 1.03-2.56; P = 0.041), Sequential Organ Failure Assessment score >5 (HR = 3.40; 95% CI 2.00-5.81; P < 0.001), and delayed inappropriate empirical antibiotic treatment (HR = 2.23; 95% CI, 1.12-4.45; P = 0.022). VAP was associated with high mortality. The major causative pathogen was drug-resistant A. baumannii. Therefore, early detection of VAP by surveillance in mechanically ventilated patients leading to earlier treatment may improve patient outcomes. Guidelines for prescribing appropriate empirical antibiotics to cover drug-resistant bacteria could be established using local epidemiological data.

Entities:  

Mesh:

Year:  2014        PMID: 25672347     DOI: 10.7883/yoken.JJID.2014.282

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  14 in total

1.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

2.  Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?

Authors:  Kimberly C Claeys; Abdalhamid M Lagnf; Jessica A Hallesy; Matthew T Compton; Alison L Gravelin; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

3.  Risk factors for ventilator-associated pneumonia among patients undergoing major oncological surgery for head and neck cancer.

Authors:  Yutao Liu; Yaxia Di; Shuai Fu
Journal:  Front Med       Date:  2017-05-11       Impact factor: 4.592

Review 4.  Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.

Authors:  Adamantia Liapikou; Katerina Dimakou; Michael Toumbis
Journal:  Ther Adv Respir Dis       Date:  2016-06-23       Impact factor: 4.031

5.  Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial.

Authors:  Yin Mo; Timothy Eoin West; Graeme MacLaren; Suchart Booraphun; Andrew Yunkai Li; Gyan Kayastha; Yie Hui Lau; Yin Tze Chew; Ploenchan Chetchotisakd; Paul Anantharajah Tambyah; Direk Limmathurotsakul; Ben Cooper
Journal:  BMJ Open       Date:  2021-05-13       Impact factor: 2.692

6.  Clinical response and outcome of pneumonia due to multi-drug resistant Acinetobacter baumannii in critically ill patients.

Authors:  Lida Shojaei; Mostafa Mohammadi; Mohammad-Taghi Beigmohammadi; Mahsa Doomanlou; Alireza Abdollahi; Mohammad Mehdi Feizabadi; Hossein Khalili
Journal:  Iran J Microbiol       Date:  2016-10

7.  The effect of ventilator-associated pneumonia on the prognosis of intensive care unit patients within 90 days and 180 days.

Authors:  Wenjuan Luo; Rui Xing; Canmin Wang
Journal:  BMC Infect Dis       Date:  2021-07-15       Impact factor: 3.090

8.  Epidemiology and Outcome of Ventilator-Associated Pneumonia in a Heterogeneous ICU Population in Qatar.

Authors:  Husain Shabbir Ali; Fahmi Yousef Khan; Saibu George; Nissar Shaikh; Jameela Al-Ajmi
Journal:  Biomed Res Int       Date:  2016-06-13       Impact factor: 3.411

9.  Ventilator-associated respiratory infection in a resource-restricted setting: impact and etiology.

Authors:  Vu Dinh Phu; Behzad Nadjm; Nguyen Hoang Anh Duy; Dao Xuan Co; Nguyen Thi Hoang Mai; Dao Tuyet Trinh; James Campbell; Dong Phu Khiem; Tran Ngoc Quang; Huynh Thi Loan; Ha Son Binh; Quynh-Dao Dinh; Duong Bich Thuy; Huong Nguyen Phu Lan; Nguyen Hong Ha; Ana Bonell; Mattias Larsson; Hoang Minh Hoan; Đang Quoc Tuan; Hakan Hanberger; Hoang Nguyen Van Minh; Lam Minh Yen; Nguyen Van Hao; Nguyen Gia Binh; Nguyen Van Vinh Chau; Nguyen Van Kinh; Guy E Thwaites; Heiman F Wertheim; H Rogier van Doorn; C Louise Thwaites
Journal:  J Intensive Care       Date:  2017-12-19

10.  Antibiotics De-Escalation in the Treatment of Ventilator-Associated Pneumonia in Trauma Patients: A Retrospective Study on Propensity Score Matching Method.

Authors:  Hu Li; Chun-Hui Yang; Li-Ou Huang; Yu-Hui Cui; Dan Xu; Chun-Rong Wu; Jian-Guo Tang
Journal:  Chin Med J (Engl)       Date:  2018-05-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.